Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Current Pharmaceutical Design|April 14, 2007
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosisJorge Busciglio, Alejandra Pelsman, Pablo Helguera, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 17, 2013
Dosage of amyloid precursor protein affects axonal contact guidance in Down syndromeLucas J Sosa, Nienke L Postma, Adriana Estrada-Bernal, et al.
Cell Reports|November 21, 2019
Suppressing Aneuploidy-Associated Phenotypes Improves the Fitness of Trisomy 21 CellsSunyoung Hwang, Jessica F Williams, Maja Kneissig, et al.
Aging Cell|July 21, 2018
Nrf2 stabilization prevents critical oxidative damage in Down syndrome cellsEmiliano Zamponi, Nahuel Zamponi, Pinar Coskun, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|June 16, 2006
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's diseaseLorena Heredia, Pablo Helguera, Soledad de Olmos, et al.
Brain : a Journal of Neurology|November 18, 2020
Evolution of neuroinflammation across the lifespan of individuals with Down syndromeLisi Flores-Aguilar, M Florencia Iulita, Olivia Kovecses, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 27, 2013
Bisphenol A delays the perinatal chloride shift in cortical neurons by epigenetic effects on the Kcc2 promoterMichele Yeo, Ken Berglund, Michael Hanna, et al.
Molecular Syndromology|February 26, 2019
Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research SocietyRoger H Reeves, Jean Delabar, Marie-Claude Potier, et al.
Journal of Alzheimer'S Disease : JAD|November 2, 2016
Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's DiseasePinar Coskun, Pablo Helguera, Zahra Nemati, et al.
Nature Communications|October 28, 2021
Repurposing cancer drugs identifies kenpaullone which ameliorates pathologic pain in preclinical models via normalization of inhibitory neurotransmissionMichele Yeo, Yong Chen, Changyu Jiang, et al.
Pageof 4